Beam Therapeutics announced positive topline results from its BEACON Phase 1/2 trial of risto-cel, a one-time gene-edited cell therapy for sickle cell disease (SCD). The trial met its primary endpoint of patients being free from severe vaso-occlusive crises (VOCs) for at least 12 consecutive months and met all safety endpoints. These results support Beam's plan to submit a Biologics License Application (BLA) to the FDA as early as the end of 2026, potentially making risto-cel the first base editing therapy approved for SCD. Detailed trial data will be presented in 2027, with interim results shared at the American Society of Hematology meeting in December 2026.
Beam Therapeutics' BEACON Phase 1/2 trial results for risto-cel come as a backdrop to a health sector where 85 of 150 US stocks rose and 56 fell on the day. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: Abeona Therapeutics Inc (ABEO) rose 2.36% to USD 2.60 with a typical hold time of 24 days and 71% buy order activity; Definium Therapeutics Inc (DFTX) increased 2.23% to USD 36.18 with 100% buy order activity and a 17-day hold; Travere Therapeutics Inc (TVTX) declined 2.19% to USD 50.50 with an 8-day hold time.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
